155 related articles for article (PubMed ID: 10975928)
1. Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma.
Xu X; Roberts SA; Pasha TL; Zhang PJ
Arch Pathol Lab Med; 2000 Sep; 124(9):1310-3. PubMed ID: 10975928
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of axillary sentinel lymph node biopsy by immunohistochemistry and multilevel sectioning in patients with breast carcinoma.
Liu LH; Siziopikou KP; Gabram S; McClatchey KD
Arch Pathol Lab Med; 2000 Nov; 124(11):1670-3. PubMed ID: 11079022
[TBL] [Abstract][Full Text] [Related]
3. Detection of micro-metastasis using cytokeratins (AE1/AE3) in haematoxylin & eosin-stained N
Sinha GM; Hegde V
Indian J Med Res; 2023 Apr; 157(4):316-321. PubMed ID: 37282394
[TBL] [Abstract][Full Text] [Related]
4. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ.
El-Tamer M; Chun J; Gill M; Bassi D; Lee S; Hibshoosh H; Mansukhani M
Ann Surg Oncol; 2005 Mar; 12(3):254-9. PubMed ID: 15827818
[TBL] [Abstract][Full Text] [Related]
5. Staining of sentinel node reticulum cells with cytokeratin antibody AE3.
Yeh IT; Miller AR
Arch Pathol Lab Med; 2002 Mar; 126(3):248-9. PubMed ID: 11860293
[No Abstract] [Full Text] [Related]
6. Cytokeratin immunostaining patterns of benign, reactive lymph nodes: applications for the evaluation of sentinel lymph node specimen.
Linden MD; Zarbo RJ
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):297-301. PubMed ID: 11759054
[TBL] [Abstract][Full Text] [Related]
7. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients.
Pendas S; Dauway E; Cox CE; Giuliano R; Ku NN; Schreiber RH; Reintgen DS
Am Surg; 1999 Jun; 65(6):500-5; discussion 505-6. PubMed ID: 10366202
[TBL] [Abstract][Full Text] [Related]
8. Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node.
Schreiber RH; Pendas S; Ku NN; Reintgen DS; Shons AR; Berman C; Boulware D; Cox CE
Ann Surg Oncol; 1999; 6(1):95-101. PubMed ID: 10030421
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor immunohistochemistry for confirmation of sentinel lymph node metastasis in cases with equivocal cytokeratin positivity.
Nguyen CV; Deavers MT; Quinones J; Huo L
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):139-45. PubMed ID: 19521277
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of sentinel lymph nodes in breast carcinoma patients.
Cohen C; Alazraki N; Styblo T; Waldrop SM; Grant SF; Larsen T
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):296-303. PubMed ID: 12607596
[TBL] [Abstract][Full Text] [Related]
11. [Detection of micrometastases in sentinel lymph nodes of breast cancer].
Zhang T; Zhang BN; Zhang HT; Sun YT
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):116-8. PubMed ID: 17645847
[TBL] [Abstract][Full Text] [Related]
12. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer?
Teng S; Dupont E; McCann C; Wang J; Bolano M; Durand K; Peltz E; Bass SS; Cantor A; Ku NN; Cox CE
Am Surg; 2000 Jun; 66(6):574-8. PubMed ID: 10888134
[TBL] [Abstract][Full Text] [Related]
13. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes.
Turner RR; Nora DT; Trocha SD; Bilchik AJ
Arch Pathol Lab Med; 2003 Jun; 127(6):673-9. PubMed ID: 12741889
[TBL] [Abstract][Full Text] [Related]
14. Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer.
Holten-Rossing H; Talman MM; Jylling AMB; Laenkholm AV; Kristensson M; Vainer B
Histopathology; 2017 Dec; 71(6):866-873. PubMed ID: 28677240
[TBL] [Abstract][Full Text] [Related]
15. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival.
Greenson JK; Isenhart CE; Rice R; Mojzisik C; Houchens D; Martin EW
Cancer; 1994 Feb; 73(3):563-9. PubMed ID: 7507795
[TBL] [Abstract][Full Text] [Related]
16. Sentinel node biopsy in ductal carcinoma in situ patients.
Pendas S; Dauway E; Giuliano R; Ku N; Cox CE; Reintgen DS
Ann Surg Oncol; 2000; 7(1):15-20. PubMed ID: 10674443
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.
Cox CE; Pendas S; Cox JM; Joseph E; Shons AR; Yeatman T; Ku NN; Lyman GH; Berman C; Haddad F; Reintgen DS
Ann Surg; 1998 May; 227(5):645-51; discussion 651-3. PubMed ID: 9605656
[TBL] [Abstract][Full Text] [Related]
18. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes.
Jakub JW; Diaz NM; Ebert MD; Cantor A; Reintgen DS; Dupont EL; Shons AR; Cox CE
Am J Surg; 2002 Oct; 184(4):302-6. PubMed ID: 12383888
[TBL] [Abstract][Full Text] [Related]
19. Detection of occult metastatic lobular carcinoma in axillary lymph nodes using anticytokeratin monoclonal antibodies.
Lachman MF; Ricci A; Pedersen CA; Cartun RW; Strumpf KB
Conn Med; 1992 Feb; 56(2):65-8. PubMed ID: 1373112
[TBL] [Abstract][Full Text] [Related]
20. Comparing touch imprint cytology, frozen section analysis, and cytokeratin immunostaining for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer.
Safai A; Razeghi A; Monabati A; Azarpira N; Talei A
Indian J Pathol Microbiol; 2012; 55(2):183-6. PubMed ID: 22771640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
